386 related articles for article (PubMed ID: 23345509)
1. Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.
Shobana R; Samal SK; Elankumaran S
J Virol; 2013 Apr; 87(7):3792-800. PubMed ID: 23345509
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells.
Raghunath S; Pudupakam RS; Allen A; Biswas M; Sriranganathan N
J Biotechnol; 2017 Oct; 260():91-97. PubMed ID: 28935568
[TBL] [Abstract][Full Text] [Related]
3. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
6. Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes.
de Graaf JF; van Nieuwkoop S; Bestebroer T; Groeneveld D; van Eijck CHJ; Fouchier RAM; van den Hoogen BG
PLoS One; 2022; 17(2):e0263707. PubMed ID: 35139115
[TBL] [Abstract][Full Text] [Related]
7. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
8. Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus.
Pfirschke C; Schirrmacher V
Int J Oncol; 2009 Apr; 34(4):951-62. PubMed ID: 19287952
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
Virol J; 2014 May; 11():84. PubMed ID: 24885546
[TBL] [Abstract][Full Text] [Related]
11. Roles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxoviruses.
Kim SH; Subbiah M; Samuel AS; Collins PL; Samal SK
J Virol; 2011 Sep; 85(17):8582-96. PubMed ID: 21680512
[TBL] [Abstract][Full Text] [Related]
12. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
13. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
14. Newcastle disease virus V protein is a determinant of host range restriction.
Park MS; García-Sastre A; Cros JF; Basler CF; Palese P
J Virol; 2003 Sep; 77(17):9522-32. PubMed ID: 12915566
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
16. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
17. [Expressing foreign genes by Newcastle disease virus for cancer therapy].
Bai FL; Tian H; Yu QZ; Renl GP; Li DS
Mol Biol (Mosk); 2015; 49(2):195-204. PubMed ID: 26065249
[TBL] [Abstract][Full Text] [Related]
18. Pathogenicity and immunogenicity of different recombinant Newcastle disease virus clone 30 variants after in ovo vaccination.
Ramp K; Topfstedt E; Wäckerlin R; Höper D; Ziller M; Mettenleiter TC; Grund C; Römer-Oberdörfer A
Avian Dis; 2012 Mar; 56(1):208-17. PubMed ID: 22545548
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]